The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Open accessAbstract
Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Chronic IFN signaling can also promote an immune suppressive environment126.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [126]
In the citing paper
“The expression of PD-L1 and MHC II, which may cause exhaustion by binding to T-cell programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3), respectively, is regulated by tumor interferon (IFN) signaling.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“In solid tumors, a tumor IFN–stimulated gene signature termed ISG.RS is associated with a multigenic program of T-cell exhaustion and worse outcomes after immune checkpoint blockade.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“One part of this program is to increase tumor expression of multiple T-cell ligands that lead to exhaustion of T cells infiltrating the TME.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“Recently, the Minn group elucidated how chronic IFN signaling mediates immunosuppression and resistance to radiation and immune checkpoint inhibitor therapy in solid tumors.2,24,54”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [24]
In the citing paper
“interferon signaling is of central importance to antitumor immune response43.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 601–700 of 1,000
Oncogenic KIT Modulates Type I IFN–Mediated Antitumor Immunity in GIST
Liu, M., Etherington, M. S., Hanna, A. N., Medina, B. D., Vitiello, G. A., Bowler, T. G., Param, N. J., Levin, L. I., Rossi, F., & DeMatteo, R. P. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0692 · Cited by 19
Immunotherapy resistance: the answers lie ahead – not in front – of us
Andrews, M. C., & Wargo, J. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0212-y · Cited by 19
Passelli, K., Repáraz, D., Kinj, R., & Herrera, F. G. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae100 · Cited by 18
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
McGeary, M. K., Damsky, W., Daniels, A. J., Lang, S. M., Xu, Q., Song, E., Huet-Calderwood, C., Lou, H. J., Paradkar, S., Micevic, G., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0514 · Cited by 19
Immune checkpoint blockade for cancer therapy: current progress and perspectives
Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 23
CD4+ T cell dysfunction in cancer
Venkatesh, H., & Fong, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241417 · Cited by 19
Wang, X., Wang, J., Wang, Q., Ding, G., Huang, Y., & Feng, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189536 · Cited by 19
Kwak, M., Erdag, G., Leick, K. M., Bekiranov, S., Engelhard, V. H., & Slingluff, C. L. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03044-5 · Cited by 18
Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors
Fenton, S. E., Ζαννίκου, Μ., Ilut, L., Fischietti, M., Ji, C., Oku, C. V., Horvath, C. M., Poole, I. C. L., Bosenberg, M., Bartom, E. T., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0684 · Cited by 19
Classen, S., Petersen, C., & Borgmann, K. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02103-8 · Cited by 19
UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma
Li, H., Liu, Y., Cheng, C., Wu, Y., Liang, S., Wu, L. L., Wang, H., Tu, C.-Y., Yao, H., Meng, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06369-9 · Cited by 18
Gu, X.-Y., Huo, J.-L., Yu, Z., Jiang, J.-C., Xu, Y.-X., & Zhao, L. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2023-0412 · Cited by 19
Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects
Wang, X., Wang, Y., Zhang, Y., Shi, H., Liu, K., Wang, F., Wang, Y., Chen, H., Shi, Y., & Wang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1357101 · Cited by 20
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness
Pallavicini, I., Frasconi, T. M., Catozzi, C., Ceccacci, E., Tiberti, S., Haas, D., Samson, J., Heuser-Loy, C., Lauson, C. B. N., Mangione, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51500-9 · Cited by 19
Voynova, E., Mahmoud, T. I., Woods, L. T., Weisman, G. A., Ettinger, R., & Braley‐Mullen, H. (2018) · ImmunoHorizons · doi:10.4049/immunohorizons.1700069 · Cited by 18
Prostate Cancer: Any Room Left for Immunotherapies?
Baxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0159 · Cited by 18
Analysis of the transcriptomic features of microsatellite instability subtype colon cancer
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-5802-2 · Cited by 17
Immunotherapy in Renal Cell Carcinoma from Poverty to the Spoiled of Choice
Massari, F., Nunno, V. D., Mollica, V., Montironi, R., Liang Cheng, C., Cimadamore, A., Blanca, A., & Antonio Lopez-beltran, B. (2019) · Immunotherapy · doi:10.2217/imt-2019-0115 · Cited by 18
Hargadon, K. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20608 · Cited by 18
USP5 stabilizes YTHDF1 to control cancer immune surveillance through mTORC1-mediated phosphorylation
Shao, N., Xi, L., Lv, Y., Idris, M., Zhang, L., Cao, Y., Xiang, J., Xu, X., Ong, B. X., Zhang, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56564-9 · Cited by 20
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 27
Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation
Fayyad‐Kazan, M., Al-Tameemi, S. A., & Ouhtit, A. (2026) · Cells · doi:10.3390/cells15050393 · Cited by 17
A novel integrated approach to predicting cancer immunotherapy efficacy
Luo, R., Chyr, J., Wen, J., Wang, Y., Zhao, W., & Zhou, X. (2022) · Oncogene · doi:10.1038/s41388-023-02670-1 · Cited by 16
Reeves, P. M., Abbaslou, M. A., Kools, F. R. W., Vutipongsatorn, K., Tong, X., Gavegnano, C., Schinazi, R. F., & Poznansky, M. C. (2017) · Oncotarget · doi:10.18632/oncotarget.21541 · Cited by 16
Ménoret, A., Buturla, J. A., Xu, M. M., Svedova, J., Kumar, S., Rathinam, V. A. K., & Vella, A. T. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0037-0 · Cited by 17
Emran, A. A., Marzese, D. M., Menon, D. R., Hammerlindl, H., Ahmed, F., Richtig, E., Duijf, P. H. G., Hoon, D. S. �., & Schaider, H. (2019) · Epigenomics · doi:10.2217/epi-2018-0173 · Cited by 19
Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy
Reading, J. L., & Quezada, S. A. (2016) · Immunity · doi:10.1016/j.immuni.2016.12.004 · Cited by 17
VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer
Passang, T., Wang, S., Zhang, H., Zeng, F., Hsu, P.-C., Wang, W., Li, J.-M., Liu, Y., Ravindranathan, S., Lesinski, G. B., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3628 · Cited by 17
Salewski, I., Kuntoff, S., Kuemmel, A., Feldtmann, R., Felix, S. B., Henze, L., Junghanß, C., & Maletzki, C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02933-4 · Cited by 16
Masamoto, Y., Chiba, A., Mizuno, H., Hino, T., Hayashida, H., Sato, T., Bando, M., Shirahige, K., & Kurokawa, M. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008018 · Cited by 17
Pathologic assessment of hepatocellular carcinoma in the era of immunotherapy: a narrative review
Wang, H., Qian, Y., Dong, H., & Cong, W. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-527 · Cited by 19
Kuras, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814403 · Cited by 18
Ma, J., Cen, Q., Wang, Q., Liu, L., & Zhou, J. Y. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101542 · Cited by 16
Naji, O., Ghouzlani, A., Rafii, S., Sadiqi, R. U., Kone, A.-S., Harmak, Z., Choukri, K., Kandoussi, S., Karkouri, M., & Badou, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399754 · Cited by 21
PTPN2: a tumor suppressor you want deleted?
Wiede, F., & Tiganis, T. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.70 · Cited by 16
DePasquale, E. A. K., Ssozi, D., Ainciburu, M., Good, J., Noel, J., Villanueva, M. A., Couturier, C., Shalek, A. K., Aranki, S. F., Mallidi, H. R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809414 · Cited by 16
Seliger, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02043 · Cited by 17
Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer
Nizzero, S., Shen, H., Mauro Ferrari, B., & Corradetti, B. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.11.008 · Cited by 16
Grigorieva, J., Asmellash, S. G., Net, L., Tsypin, M., Röder, H., & Roder, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030838 · Cited by 16
Sørensen, M. D., Olsen, R. F. S., Burton, M., Kavan, S., Petterson, S. A., Thomassen, M., Kruse, T. A., Meyer, M., & Kristensen, B. W. (2024) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.13016 · Cited by 15
Goto, N., Agudo, J., & Yilmaz, Ö. H. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.04.016 · Cited by 18
Differential assembly of mouse and human tumor microenvironments
Courau, T., Jaszczak, R. G., Samad, B., Flynn, E., Chew, N. W., Reeder, G. C., Tsui, J. L., Teklu, S., Pass, L. F., Edwards, A. W., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02505-7 · Cited by 18
Linghu, D., Song, J., Gu, L., Liu, C., Liu, B., Yang, R., Chen, Q., Yao, J., Manickam, S. P., Sundhar, N., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010926 · Cited by 15
Pu, Y., Lu, X., Yang, X., Yang, Y., Wang, D., Li, M., Guan, W. P., & Xu, M. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-686 · Cited by 15
Song, P. N., Mansur, A., Lü, Y., Manna, D. D., Burns, A. C., Samuel, S. L., Heinzman, K. A., Lapi, S. E., Yang, E. S.-H., & Sorace, A. G. (2022) · Cancers · doi:10.3390/cancers14041015 · Cited by 15
Zhu, M., Li, X., Xu, C. W., Ye, F., Ye, F., Li, X., Hu, Z., Zhang, L., Nie, J. J., & Li, X. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01252-6 · Cited by 16
Lymph node metastasis fuels systemic disease
Ventre, K. S., Karakousi, T. R., & Lund, A. W. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.003 · Cited by 15
Tabanelli, V., Melle, F., Motta, G., Mazzara, S., Fabbri, M., Agostinelli, C., Calleri, A., Corvo, M. D., Fiori, S., Lorenzini, D., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007046 · Cited by 15
Highlights into historical and current immune interventions for cancer
Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15
XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells
Zou, T., Zhou, M., Gupta, A. A., Zhuang, P., Fishbein, A. R., Wei, H. Y., Capcha-Rodriguez, D., Zhang, Z., Cherniack, A. D., & Meyerson, M. M. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113600 · Cited by 15
IFNγ-Induced Bcl3, PD-L1 and IL-8 Signaling in Ovarian Cancer: Mechanisms and Clinical Significance
Reddy, S. P., Sadia, F. Z., Vančura, A., & Vancurova, I. (2024) · Cancers · doi:10.3390/cancers16152676 · Cited by 16
Jagadeeshan, S., Prasad, M., Ortiz-Cuàran, S., Grégoire, V., Saintigny, P., & Elkabets, M. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.04.004 · Cited by 14
Combining Radiation Therapy With Interferons: Back to the Future
Goedegebuure, R. S. A., Vonk, C. M., Kooij, L. P., Derks, S., & Thijssen, V. L. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.02.016 · Cited by 16
Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy
Gough, M. J., Sharon, S., Crittenden, M. R., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.002 · Cited by 15
Type I Interferons as Joint Regulators of Tumor Growth and Obesity
Gessani, S., & Belardelli, F. (2021) · Cancers · doi:10.3390/cancers13020196 · Cited by 15
Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play
Donlon, N. E., Power, R. F., Hayes, C., Davern, M., Reynolds, J. V., & Lysaght, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031071 · Cited by 15
Penter, L., Gohil, S. H., Huang, T., Thrash, E. M., Schmidt, D., Li, S., Severgnini, M., Neuberg, D. S., Hodi, F. S., Livak, K. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004335 · Cited by 15
Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer
Ding, P., Wen, L., Tong, F., Zhang, R., Huang, Y., & Dong, X. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.104 · Cited by 15
Jiao, Z., Feng, X., Cui, Y., Wang, L., Gan, J., Zhao, Y., & Meng, Q. (2022) · BMC Cancer · doi:10.1186/s12885-022-09951-0 · Cited by 15
Understanding genetic determinants of resistance to immune checkpoint blockers
Aspeslagh, S., Chabanon, R. M., Champiat, S., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.020 · Cited by 16
Turan, T., Kongpachith, S., Halliwill, K. D., Roelands, J. P., Hendrickx, W., Marincola, F. M., Hudson, T. J., Jacob, H. J., Bedognetti, D., Samayoa, J. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01193-w · Cited by 15
CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies
Zhang, W., Yang, L.-Y., & Fan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1622433 · Cited by 14
Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 16
The Influence of Carbon Nanotubes and Graphene on Immune Cells
Frumento, D., & Ţălu, Ş. (2025) · Cells · doi:10.3390/cells14211700 · Cited by 14
Marcucci, F., & Rumio, C. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03606-8 · Cited by 14
STUB1 is an intracellular checkpoint for interferon gamma sensing
Ng, S., Lim, S., Sim, A. C. N., Mangadu, R., Lau, A., Zhang, C., Martinez, S. B., Chandramohan, A., Lim, U.-M., Ho, S. S. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18404-4 · Cited by 14
Type I and II interferon signaling in colorectal cancer liver metastasis
Mödl, B., Moritsch, S., Zwolanek, D., & Eferl, R. (2022) · Cytokine · doi:10.1016/j.cyto.2022.156075 · Cited by 18
Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma
Horowitch, B., Lee, D. Y., Ding, M., Martínez-Morilla, S., Aung, T. N., Ouerghi, F., Wang, X., Wei, W., Damsky, W., Sznol, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0215 · Cited by 14
Self-citationJacobo, M. J., Donnella, H. J., Sobti, S., Kaushik, S., Goga, A., & Bandyopadhyay, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-53999-w · Cited by 13
Kang, J. A., Kim, Y. J., Jang, K. Y., Moon, H. W., Lee, H., Lee, S., Song, H. K., Cho, S. W., Yoo, Y. S., Han, H. G., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01194-2 · Cited by 15
Han, Y., Zou, C., Liu, T., Cheng, W. M., Cheng, P., & Wu, A. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03131-7 · Cited by 14
The ending is not the end: Lymph node metastasis in oral squamous cell carcinoma
Wei, L.-Y., Li, Z., Xu, Z.-Y., Wang, G.-R., Xiao, Y., Liu, B., & Bu, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113917 · Cited by 16
Morisada, M. V., Chamberlin, M. M., & Allen, C. T. (2018) · Head & Neck · doi:10.1002/hed.25101 · Cited by 14
Atomic Force Microscopy in Mechanoimmunology Analysis: A New Perspective for Cancer Immunotherapy
Kristi, N., Gafur, A., Kong, L., Ma, X., Ye, Z., & Wang, G. (2020) · Biotechnology Journal · doi:10.1002/biot.201900559 · Cited by 14
Li, W., Zhan, M., Quan, Y., Wang, H., Hua, S., Li, Y., Zhang, J., Lu, L., & Cui, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106227 · Cited by 14
Advancing oral cancer care: nanomaterial-driven diagnostic and therapeutic innovations
Chen, Y., Cai, S., Liu, F., & Liu, M. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10027-5 · Cited by 15
Mapping intratumor heterogeneity across layers for advancing immunotherapy
Marine, J., Bartok, O., Sagie, S., Vitiello, P. P., Bardelli, A., Weller, C., Chang, T., Tonelli, C., Spranger, S., Ruppin, E., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.025 · Cited by 16
An IFNγ/STAT1/JMJD3 Axis Induces ZEB1 Expression and Promotes Aggressiveness in Lung Adenocarcinoma
Yang, J., Wang, X. B., Huang, B. Y., Liu, R., Xiong, H., Ye, F., Zeng, C., Fu, X., & Li, L. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0948 · Cited by 13
The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
Gauci, M.-L., Giustiniani, J., Lepelletier, C., Garbar, C., Thonnart, N., Dumaz, N., Foussat, A., Lebbé, C., Bensussan, A., & Marie‐Cardine, A. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03199-0 · Cited by 13
Serpico, A. F., Pisauro, C., & Grieco, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127623 · Cited by 14
Du, W.-Y., Masuda, H., Nagaoka, K., Yasuda, T., Kuge, K., Seto, Y., Kakimi, K., & Nomura, S. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01514-5 · Cited by 13
Taylor, C., Patterson, K. M., Friedman, D., Bacot, S. M., Feldman, G. M., & Wang, T. (2024) · Cancers · doi:10.3390/cancers16173071 · Cited by 17
Wang, P., Zhao, X., Ying, Y., Huang, S., Liu, T., Zheng, R., Xie, F., Sun, W. C., & Liu, Z. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202412497 · Cited by 13
The curious case of type I interferon signaling in cancer
Chhipa, A. S., Boscaro, V., Gallicchio, M., & Patel, S. S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189204 · Cited by 13
Angelicola, S., Giunchi, F., Ruzzi, F., Frascino, M., Pitzalis, M., Scalambra, L., Semprini, M. S., Pittino, O. M., Cappello, C., Siracusa, I., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06023-8 · Cited by 13
Progress in personalized immunotherapy for patients with brain metastasis
Patel, L. R., Kolundžić, N., & Abedalthagafi, M. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00812-0 · Cited by 14
Tarbell, K. V., & Egen, J. G. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir1017-400r · Cited by 15
Cancer vaccines: An unkept promise?
Kamath, V. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.006 · Cited by 13
Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
Thoidingjam, L. K., Blouin, C. M., Gaillet, C., Brion, A., Solier, S., Niyomchon, S., Marjou, A. E., Mouasni, S., Sepulveda, F. E., Basile, G. D. S., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202205231 · Cited by 13
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy
Behrouzieh, S., Sheida, F., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1996230 · Cited by 13
Beck, L. D., Awad, R. M., Basso, V., Casares, N., Ridder, K. D., Vlaeminck, Y. D., Gnata, A., Goyvaerts, C., Lecocq, Q., José‐Eneriz, E. S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.799636 · Cited by 12
Sun, K., Zhang, X., Lao, M., He, L., Wang, S., Yang, H., Xu, J. M., Tang, J., Hong, Z., Song, J., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.021 · Cited by 12
Yan, S., Zhang, X., Lin, Q., Du, M., Li, Y., He, S., Chen, J., Li, X., Bei, J., Chen, S., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03789-0 · Cited by 14
Ding, T., Chen, Q., Liu, H., Zhang, H., Sun, Y., Zhao, L., Gao, Y., & Wei, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37511 · Cited by 12
Interplay of RNA m6A Modification-Related Geneset in Pan-Cancer
Zhang, B., Hao, Y., Liu, H., Wu, J., Lu, L., Wang, X., Bajpai, A. K., & Yang, X. (2024) · Biomedicines · doi:10.3390/biomedicines12102211 · Cited by 13
Hai, L., Friedel, D., Hinz, F. E., Hoffmann, D. C., Doubrovinskaia, S., Rohdjess, H., Weidenauer, K., Denisova, E., Scheffler, G. T., Keßler, T., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae251 · Cited by 12
Biomolecular condensates: A new lens on cancer biology
Jiang, L., & Kang, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189245 · Cited by 13
Sævarsson, T., de Lomana, A. L. G., Sánchez, Ó., van Esch, V., Ragnarsson, G. B., Brynjolfsson, S. F., Steingrı́msson, E., & Einarsdottir, B. O. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01963-6 · Cited by 13
Blanchard, L., Vina, E., Ljubetic, J., Meneur, C., Tarroux, D., Baez, M., Marino, A. E., Ortéga, N., Knorr, D. A., Ravetch, J. V., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102141 · Cited by 14
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells
Xia, M., Luo, T. Y., Shi, Y., Wang, G., Tsui, H., Harari, D., & Spaner, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000478 · Cited by 12
Metadata
- Authors
- Benci, J. L., Xu, B., Qiu, Y., Wu, T. J., Dada, H., Twyman-Saint Victor, C., Cucolo, L., Lee, D. S. M., Pauken, K. E., Huang, A. C., Gangadhar, T. C., Amaravadi, R. K., Schuchter, L. M., Feldman, M. D., Ishwaran, H., Vonderheide, R. H., Maity, A., Wherry, E. J., & Minn, A. J.
- Affiliations
- University of Pennsylvania (US)
- University of Miami (US)
- Parker Institute for Cancer Immunotherapy (US)
- Corresponding author
- Minn, Andy J.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 167
- Issue
- 6
- Pages
- 1540-1554.e12
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC5385895
- OpenAlex
- W2558219863
- Cited by
- 1,216
- References
- 42
- Citations by year
- 2026: 150 · 2025: 124 · 2024: 127 · 2023: 135 · 2022: 128 · 2021: 140 · 2020: 140 · 2019: 114 · 2018: 92 · 2017: 64 · 2016: 1
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo
- Funders
- Melanoma Research Alliance
- Parker Institute for Cancer Immunotherapy
- Robertson Foundation
- Cancer Research Institute Irvington Fellowship
- NIH (P50CA174523, R01CA163739, R01CA158186, P30CA016520, U19AI082630, R01AI105343, U01AI095608, P01AI112521)
- Basser Research Center for BRCA
- Abramson Cancer Center Translational Center of Excellence in Pancreatic Cancer
- Department of Defense Era of Hope Scholar (W81XWH-09-1-0339)
- NCI (R01CA172651)
- Merck
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitor resistance, type I interferon, interferon-gamma, PD-1 pathway, PD-L1, STAT1, interferon-stimulated genes, T cell inhibitory receptors, T cell exhaustion, radiotherapy, tumor immune microenvironment, resistance biomarkers, anti-PD-1 therapy
- MeSH terms
- Animals, Humans, Interferons, Melanoma, Neoplasm Transplantation, T-Lymphocytes, Radioimmunotherapy, Drug Resistance, Neoplasm, Cell Line, Tumor, STAT1 Transcription Factor, Mice, B7-H1 Antigen, CTLA-4 Antigen, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
